Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
- Conditions
- Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
- Interventions
- Biological: ATA188Drug: Placebo
- Registration Number
- NCT03283826
- Lead Sponsor
- Atara Biotherapeutics
- Brief Summary
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).
- Detailed Description
This is a multicenter, 2 part study in adult participants with progressive forms of MS (PPMS/SPMS) with an open-label, single-arm, sequential dose-escalation period (Part 1) and a double-blind, randomized, placebo-controlled dose-expansion period (Part 2) followed by open-label extension (OLE) period. Part 2 and the OLE have been initiated by the sponsor's discretion based on a review of data from the dose-escalation cohorts.
This study will evaluate the safety and efficacy of ATA188 administered by intravenous (IV) infusion. ATA188 will be selected for each participant based on matching 2 or more human leukocyte antigen (HLA) alleles shared between ATA188 and the participant, at least 1 of which is a HLA-restricting allele.
In Part 1, participants received 2 cycles of ATA188 and entered 12 months follow-up period after the last dose of ATA188. Participants who completed at least the first year of the dose-escalation period and were active in the study have entered the OLE period. In OLE period, participants will receive the same RP2D assigned to Part 2 participants at the time of the Part 1 participant's first dose in each year of the OLE. In OLE period, participants will receive 1 cycle of ATA188 treatment every 12 months (Q12M) for up to 4 years (ie, Years 2 to 5). Otherwise, end of study (EOS) visit will be conducted at 24 months after Cycle 1 Day 1.
In Part 2, participants will be randomized in 1:1 ratio to receive ATA188 at the RP2D or matching placebo, stratified by progressive MS diagnosis (PPMS vs SPMS) and any prior exposure to anti-CD20 therapy (yes vs no). Participants will receive 2 cycles of ATA188 at the RP2D or matching placebo and will be followed for at least 12 months after the first dose of study drug (ie, Year 1). In second year (Year 2), participants who received placebo in Year 1 will receive 2 cycles of ATA188 at the RP2D assigned at randomization and participants who received ATA188 at the RP2D in Year 1 will receive 1 cycle of ATA188 (at the RP2D assigned at randomization) and 1 cycle of placebo to maintain the blind. Participants who complete Year 2 will enter the OLE period to receive ATA188 Q12M for up to 3 years (ie, Years 3 to 5) at the RP2D that was last selected by the sponsor for Part 2. The end of study visit will be scheduled at 5 years (60 months) after the first dose of study drug (ie, Cycle 1 Day 1).
Based on interim analysis, the recruitment for Parts 1and 2 have completed.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 134
- For Part 1: History of progressive forms of MS (PPMS or SPMS), as defined by the 2010 Revised McDonald criteria for the diagnosis of MS
- For Part 1: 18 to < 66 years of age
- For Part 1: EDSS scores of 3.0 to 7.0. Participants with EDSS scores of 6.5 to 7.0 must retain measurable upper limb function as assessed by the 9-hole Peg Test (9HPT).
- For Part 2: Current diagnosis of a progressive form of MS (PPMS or SPMS) as defined by the 2017 Revised McDonald criteria
- For Part 2:18 to < 61 years of age
- For Part 2:EDSS scores of 3.0 to 6.5
- Positive EBV serology
- Willing and able to provide written informed consent
- Clinical relapse as follows: For Part 1: Active clinical relapse between providing informed consent and the first dose of study drug. For Part 2: Documented clinical and/or radiological relapse for 2 years prior to screening, including gadolinium (Gd)-enhancing lesion(s) on any brain MRI scans available during this period (A participant will also be considered ineligible if any clinical and/or radiological relapse is reported between screening and the first dose of study drug.)
- Concurrent serious uncontrolled or unresolved medical condition, such as infection, limiting protocol compliance or exposing the subject to unacceptable risk
- Positive serology and/or nucleic acid testing (NAT) for human immunodeficiency virus (HIV), active hepatitis B virus (HBV) infection or carrier status for HBV, active hepatitis C virus (HCV) infection
- For Part 1: Positive serology for syphilis or human T cell lymphotrophic virus I/II
- Uncontrolled psychosis, uncontrolled depression or suicide risk, substance dependence, or any other psychiatric condition that may compromise the ability to participate in this trial
- Clinically significant abnormalities of full blood count, renal function, or hepatic function
- Any contraindication to MRI and/or Gd, eg., any object that is reactive to strong static magnetic, pulsed-gradient fields including any metallic fragments or foreign body (eg, aneurysm clip[s], pacemakers, electronic implants, shunts)
- Any history of cancer (as exceptions, successfully treated non-melanoma skin cancer or carcinoma in situ of the cervix with a < 5% chance of recurrence within 12 months of providing informed consent are allowed.)
- Prior therapy with corticosteroids (within 2 weeks before Cycle 1 Day 1)
- Prior therapy (30 days) B-cell depleting agent (eg, anti-CD20 agents such as ocrelizumab); participant must be progressing despite therapy to be eligible
- For Part 1: Prior therapy (6 half-lives or 30 days whichever is longer) with cladribine, glatiramer acetate, interferon β, dimethyl fumarate, methotrexate, azathioprine, cyclosporine, fingolimod, natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin or similar anti-T-cell antibody therapy, or any other investigational product
- For Part 1: Any previous treatment with alemtuzumab, ablative stem cell transplant, or EBV T-cell therapy
- For Part 2: Prior therapy (6 half-lives or 30 days whichever is longer) with IV immunoglobin, plasmapheresis, Bruton's tyrosine kinase inhibitors, all sphingosine 1-phosphate receptor modulators (eg, fingolimod), glatiramer acetate, interferon β, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators (eg, dimethyl fumarate), methotrexate, azathioprine, cyclosporine, natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin or similar anti-T-cell antibody therapy, or any other investigational product
- For Part 2: Any previous treatment with cladribine, alemtuzumab, ablative stem cell transplant, or EBV T-cell therapy
- Unresolved reactions from previous therapies that may, in the investigator's opinion, impact the safety of the participant or the conduct of this study
- Unwilling to use protocol specified contraceptive methods
- Women who are breastfeeding
- Pregnancy
- Inability or unwillingness to comply with study procedures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description ATA188 ATA188 Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description. Placebo Placebo Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).
- Primary Outcome Measures
Name Time Method Part 1: Recommended Part 2 dose of ATA188 monotherapy Day 1 to Day 35 of Cycle 1 for each participant in dose escalation part (approximately 1 year) Part 1: Incidence of adverse events At 12 months after the first dose of study drug Part 2: Percentage of participants with confirmed expanded disability status scale (EDSS) improvement at 12 months At 12 months after the first dose of study drug Part 1: Incidence of clinically significant changes in laboratory tests, electrocardiograms (ECGs), and vital signs At 12 months after the first dose of study drug
- Secondary Outcome Measures
Name Time Method Part 2: Percentage of participants with confirmed EDSS improvement at 15 months At 15 months after the first dose of study drug Part 1: Change from baseline in EDSS score At 12 months after the first dose of study drug Part 2: Change from baseline in immunoglobulin G (IgG) index At 9 months after the first dose of study drug Part 2: Percentage of participants with sustained disability improvement (SDI; ie, confirmed EDSS improvement or 20% decrease in timed 25-foot walk [T25W]) at 12 months At 12 months after the first dose of study drug Part 2: Percentage of participants with SDI at 15 months At 15 months after the first dose of study drug
Trial Locations
- Locations (31)
Stanford University
🇺🇸Palo Alto, California, United States
Washington University in St. Louis
🇺🇸Saint Louis, Missouri, United States
University of California, San Diego
🇺🇸La Jolla, California, United States
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
Columbia University Medical Center-The Neurological Institute of New York
🇺🇸New York, New York, United States
Recherche Sepmus Inc.
🇨🇦Greenfield Park, Quebec, Canada
PMG Research of Piedmont Healthcare
🇺🇸Mooresville, North Carolina, United States
Advanced Neurosciences Institute ANI - Franklin
🇺🇸Franklin, Tennessee, United States
Dent Neurologic Institute
🇺🇸Amherst, New York, United States
Inland Northwest Research LLC
🇺🇸Spokane, Washington, United States
Kaiser Permanente MS Clinic Los Angeles
🇺🇸Los Angeles, California, United States
Fort Wayne Neurological Center
🇺🇸Fort Wayne, Indiana, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
Unity Health Toronto/St. Michael's Hospital
🇨🇦Toronto, Ontario, Canada
Neurology Associates, PA-Maitland
🇺🇸Maitland, Florida, United States
University of Rochester Medical Center - URMC
🇺🇸Rochester, New York, United States
Royal Brisbane and Women's Hospital
🇦🇺Brisbane, Queensland, Australia
Advanced Neurology
🇺🇸Fort Collins, Colorado, United States
University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center
🇺🇸Kansas City, Kansas, United States
Premier Neurology P.C.
🇺🇸Greer, South Carolina, United States
Fraser Health Multiple Sclerosis Clinic
🇨🇦Burnaby, British Columbia, Canada
Dragonfly Research
🇺🇸Wellesley, Massachusetts, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
University of Colorado
🇺🇸Aurora, Colorado, United States
Vanderbilt Comprehensive Multiple Sclerosis Center
🇺🇸Nashville, Tennessee, United States
University of California San Francisco
🇺🇸San Francisco, California, United States
University of South Florida, Morsani College of Medicine
🇺🇸Tampa, Florida, United States
MS Center of Greater Washington
🇺🇸Vienna, Virginia, United States
Griffith University, School of Medicine
🇦🇺Southport, Queensland, Australia